NIPH Clinical Trials Search

Basic Information

Recruitment status	completed
Health condition(s) or Problem(s) studied
Date of first enrollment	15/02/2019
Target sample size	1140
Countries of recruitment	Japan,Asia except Japan,North America,Europe
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : INN of investigational material : pembrolizumab, paclitaxel, doxorubicin hydrochloride, epirubicin, cyclophosphamide Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : paclitaxel, doxorubicin hydrochloride, epirubicin, cyclophosphamide Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcome	efficacy
Secondary Outcome	safety efficacy

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Female
Include criteria
Exclude criteria